Abstract
Diffuse large B-cell lymphoma (DLBCL) stands as a formidable challenge in the landscape of non-Hodgkin’s lymphomas. This review illuminates the remarkable strides made in comprehending DLBCL’s molecular intricacies and devising targeted treatments. DLBCL, the most prevalent non-Hodgkin’s lymphoma, has seen transformative progress in its characterization. Genetic investigations, led by high-throughput sequencing, have unveiled recurrent mutations in genes such as MYC, BCL2, and BCL6, casting light on the underlying genetic chaos propelling DLBCL’s aggressiveness. A pivotal facet of this understanding centers on cell signaling pathways. Dysregulation of B-cell receptor (BCR) signaling, NF-κB, PI3K/Akt/mTOR, JAK/STAT, Wnt/β-Catenin, and Toll-like receptor pathways plays a critical role in DLBCL pathogenesis, offering potential therapeutic targets. DLBCL’s complex tumor microenvironment (TME) cannot be overlooked. The dynamic interplay among tumor cells, immune cells, stromal components, and the extracellular matrix profoundly influences DLBCL’s course and response to therapies. Epigenetic modifications, including DNA methylation and histone changes, add another layer of intricacy. Aberrant epigenetic regulation plays a significant role in lymphomagenesis, offering prospects for epigenetic-based therapies. Promisingly, these molecular insights have spurred the development of personalized treatments. Targeted therapies and immunotherapies, guided by genomic profiling and molecular classification, are emerging as game-changers in DLBCL management. In conclusion, this review underscores the remarkable strides in understanding DLBCL’s molecular underpinnings, spanning genetics, cell signaling, the tumor microenvironment, and epigenetics. These advances pave the way for more effective, personalized treatments, renewing hope for DLBCL patients.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
Data Availability
The data is provided in published article and further raw data can be requested to corresponding author.
References
Agarwal P, Kabir FM, DeInnocentes P, Bird RC (2012) Tumor suppressor gene p16/INK4A/CDKN2A and its role in cell cycle exit, differentiation, and determination of cell fate. Tumor Suppressor Genes 3(10):27882
Alaggio R, Amador C, Anagnostopoulos I, Attygalle AD, Araujo IBO, Berti E et al (2022) The 5th edition of the world health organization classification of haematolymphoid tumours: lymphoid neoplasms. Leukemia. 5th ed. 36(7):1720–48. https://doi.org/10.1038/s41375-022-01620-2
Andersen CL, Asmar F, Klausen T, Hasselbalch H, Grønbæk KJLRR (2012) Somatic mutations of the crebbp and EP300 genes affect response to histone deacetylase inhibition in malignant DLBCL clones. Leuk Res Rep 2(1):1–3. https://doi.org/10.1016/j.lrr.2012.10.002
Bakhshi TJ, Georgel PT (2020) Genetic and epigenetic determinants of diffuse large B-cell lymphoma. Blood Cancer J 10(12):123. https://doi.org/10.1038/s41408-020-00389-w
Basso K, Dalla-Favera RNRI (2015) Germinal centres and B cell lymphomagenesis. Nat Rev Immunol 15(3):172–84. https://doi.org/10.1038/nri3814
Baylin SB, Jones PA (2011) A decade of exploring the cancer epigenome—biological and translational implications. Nat Rev Cancer 11(10):726–734. https://doi.org/10.1038/nrc3130
Bedsaul JR, Carter NM, Deibel KE, Hutcherson SM, Jones TA, Wang Z, Yang C, Yang YK, Pomerantz JL (2018) Mechanisms of regulated and dysregulated CARD11 signaling in adaptive immunity and disease. Front Immunol 9:2105
Béguelin W, Popovic R, Teater M, Jiang Y, Bunting KL, Rosen M et al (2013) EZH2 is required for germinal center formation and somatic EZH2 mutations promote lymphoid transformation. Cancer Cell 23(5):677–692. https://doi.org/10.1016/j.ccr.2013.04.011
Berendsen MR, Stevens WBC, van den Brand M, van Krieken JH, Scheijen BJC (2020) Molecular genetics of relapsed diffuse large B-cell lymphoma: insight into mechanisms of therapy resistance. Cancers (basel) 12(12):3553. https://doi.org/10.3390/cancers12123553
Bohers E, Mareschal S, Bouzelfen A, Marchand V, Ruminy P, Maingonnat C, Ménard AL, Etancelin P, Bertrand P, Dubois S, Alcantara M (2014) Targetable activating mutations are very frequent in GCB and ABC diffuse large B-cell lymphoma. Genes Chromosom Cancer 53(2):144–53
Borghesi L, Milcarek C (2006) From B cell to plasma cell: regulation of V (D) J recombination and antibody secretion. Immunol Res 36:27–32
Burger JA, Wiestner A (2018) Targeting B cell receptor signalling in cancer: preclinical and clinical advances. Nat Rev Cancer 18(3):148–167. https://doi.org/10.1038/nrc.2017.121
Burrows PD, Cooper MD (1997) B cell development and differentiation. Curr Opin Immunol 9(2):239–44
Campo E, Swerdlow SH, Harris NL, Pileri S, Stein H, Jaffe ES (2011) The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications. Blood J Am Soc Hematol 117(19):5019–32. https://doi.org/10.1182/blood-2011-01-293050
Chambwe N, Kormaksson M, Geng H, De S, Michor F, Johnson NA et al (2014) Variability in DNA methylation defines novel epigenetic subgroups of DLBCL associated with different clinical outcomes. Blood J Am Soc Hematol 123(11):1699–1708
Chan HM, La Thangue NB (2001) p300/CBP proteins: HATs for transcriptional bridges and scaffolds. J Cell Sci 114(13):2363–73. https://doi.org/10.1242/jcs.114.13.2363
Chapuy B, Stewart C, Dunford AJ, Kim J, Kamburov A, Redd RA et al (2018) Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes. Nat Med 24(5):679–690. https://doi.org/10.1038/s41591-018-0016-8
Chapuy B, Stewart C, Dunford AJ, Kim J, Kamburov A, Redd RA, Lawrence MS, Roemer MG, Li AJ, Ziepert M, Staiger AM (2018) Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes. Nat Med 24(5):679–90. https://doi.org/10.1038/s41591-018-0016-8
Chen H, Liu H, Qing G (2018) Targeting oncogenic Myc as a strategy for cancer treatment. Signal Transduct Target Ther 3(1):5
Choi Y, Chan AP (2015) PROVEAN web server: a tool to predict the functional effect of amino acid substitutions and indels. Bioinformatics 31(16):2745–7. https://doi.org/10.1093/bioinformatics/btv195
Choi Y, Sims GE, Murphy S, Miller JR, Chan AP (2012). Predicting the functional effect of amino acid substitutions and indels. https://doi.org/10.1371/journal.pone.0046688
Choi Y (2012) A fast computation of pairwise sequence alignment scores between a protein and a set of single-locus variants of another protein. In: Proceedings of the A.C.M. conference on bioinformatics, computational biology and biomedicine (414–7). https://doi.org/10.1145/2382936.2382989
Clozel T, Yang S, Elstrom R.L (2017) Epigenetic alterations in B-cell non-Hodgkin lymphoma. Front Genet 8:69
Compagno M et al (2009) Mutations of multiple genes cause deregulation of NF-B in diffuse large B-cell lymphoma. Nature 459(7247):717–21. https://doi.org/10.1038/nature07968
Coupland S (2013) Molecular pathology of lymphoma. Eye 27:180–189. https://doi.org/10.1038/eye.2012.247
Crump NT, Milne TA (2019) Why are so many MLL lysine methyltransferases required for normal mammalian development? Cell Mol Life Sci 76:2885–98
Cucco F, Barrans S, Sha C, Clipson A, Crouch S, Dobson R et al (2020) Distinct genetic changes reveal evolutionary history and heterogeneous molecular grade of DLBCL with MYC/BCL2 double-hit. Leukemia 34(5):1329–1341. https://doi.org/10.1038/s41375-019-0691-6
Davis RE, Ngo VN, Lenz G, Tolar P, Young RM, Romesser PB, Kohlhammer H, Lamy L, Zhao H, Yang Y, Xu W (2010) Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma. Nature 463(7277):88–92. https://doi.org/10.1038/nature08638
Dawson MA, Kouzarides T (2012) Cancer epigenetics: from mechanism to therapy. Cell 150(1):12–27. https://doi.org/10.1016/j.cell.2012.06.013
de Barrios O, Meler A, Parra M (2020) MYC’s fine line between B cell development and malignancy. Cells 9(2):523. https://doi.org/10.3390/cells9020523
de Groen RAL, Schrader AMR, Kersten MJ, Pals ST, Vermaat JSP (2019) MYD88 in the driver’s seat of B-cell lymphomagenesis: from molecular mechanisms to clinical implications. Haematologica 104(12):2337–2348. https://doi.org/10.3324/haematol.2019.227272
Deguine J, Barton GM (2014) MyD88: a central player in innate immune signaling. F1000prime Rep 6:97. https://doi.org/10.12703/P6-97
Duan R, Du W, Guo W (2020) EZH2: a novel target for cancer treatment. J Hematol Oncol 13(1):104. https://doi.org/10.1186/s13045-020-00937-8
Dunleavy K, Erdmann T, Lenz G (2018) Targeting the B-cell receptor pathway in diffuse large B-cell lymphoma. Cancer Treat Rev 1(65):41–46. https://doi.org/10.1016/j.ctrv.2018.01.002
Dutto I, Scalera C, Prosperi E (2018) CREBBP and p300 lysine acetyl transferases in the DNA damage response. Cell Mol Life Sci 75:1325–38
Dylke J, Lopes J, Dang-Lawson M, Machtaler S, Matsuuchi L (2007) Role of the extracellular and transmembrane domain of Igα/β in assembly of the B cell antigen receptor (BCR). Immunol Lett 112(1):47–57. https://doi.org/10.1016/j.imlet.2007.06.005
Elbadawy M, Usui T, Yamawaki H, Sasaki K (2019) Emerging roles of C-Myc in cancer stem cell-related signaling and resistance to cancer chemotherapy: a potential therapeutic target against colorectal cancer. Int J Mol Sci 20(9):2340. https://doi.org/10.3390/ijms20092340
Esteller M (2002) CpG island hypermethylation and tumor suppressor genes: a booming present, a brighter future. Oncogene 21(35):5427–5440. https://doi.org/10.1038/sj.onc.1205600
Forbes SA, Bindal N, Bamford S, Cole C, Kok CY, Beare D, Jia M, Shepherd R, Leung K, Menzies A, Teague JW (2010) COSMIC: mining complete cancer genomes in the Catalogue of Somatic Mutations in Cancer. Nucleic Acids Res 39:945–50
Froimchuk E, Jang Y, Ge KJG (2017) Histone H3 lysine 4 methyltransferase KMT2D. Gene. 627:337–42. https://doi.org/10.1016/j.gene.2017.06.056
Frontzek F, Lenz G (2019) Novel insights into the pathogenesis of molecular subtypes of diffuse large B-cell lymphoma and their clinical implications. Expert Rev Clin Pharmacol 12(11):1059–67
George B, Chowdhury SM, Hart A, Sircar A, Singh SK, Nath UK et al (2020) Ibrutinib resistance mechanisms and treatment strategies for B-cell lymphomas. Cancers 12(5):1328. https://doi.org/10.3390/cancers12051328
Giam M, Huang DC, Bouillet P (2008) BH3-only proteins and their roles in programmed cell death. Oncogene 27(1):S128-36. https://doi.org/10.1038/onc.2009.50
Gouveia GR, Siqueira SA, Pereira J (2012) Pathophysiology and molecular aspects of diffuse large B-cell lymphoma. Rev Bras Hematol Hemoter 34(6):447–451. https://doi.org/10.5581/1516-8484.20120111
Gunawardana J, Chan FC, Telenius A, Woolcock B, Kridel R, Tan KL et al (2014) Recurrent somatic mutations of PTPN1 in primary mediastinal B cell lymphoma and Hodgkin lymphoma. Nat Genet 46(4):329–35. https://doi.org/10.1038/ng.2900
Han CH, Batchelor TT (2017) Diagnosis and management of primary central nervous system lymphoma. Cancer 123(22):4314–4324. https://doi.org/10.1002/cncr.30965
Herviou L, Cavalli G, Cartron G, Klein B, Moreaux JJO (2016) EZH2 in normal hematopoiesis and hematological malignancies. Oncotarget 7(3):2284–96. https://doi.org/10.18632/oncotarget.6198
Honjo T, Kinoshita K, Muramatsu M (2002) Molecular mechanism of class switch recombination: linkage with somatic hypermutation. Ann Rev Immunol 20(1):165–96. https://doi.org/10.1146/annurev.immunol.20.090501.112049
Huang Y, Yan X, Cai S, Cai J, Jian J, Lu Y et al (2016) Characterization and expression analysis of B cell receptor accessory molecule CD79 gene in humphead snapper (Lutjanus sanguineus). J Ocean Univ China 15(2):318–326. https://doi.org/10.1007/s11802-016-2816-0
Ishqi, H. M., Husain, M. A., Rehman, S. U., Sarwar, T., & Tabish, M. (2018). Identification and expression of alternatively spliced novel isoforms of cancer associated MYD88 lacking death domain in mouse. Molecular biology reports, 45(5), 699-711. https://doi.org/10.1007/s11033-018-4209-5
Jiang Y, Melnick A (2015) The epigenetic basis of diffuse large B-cell lymphoma. Hematol. 52(2):86–96. https://doi.org/10.1053/j.seminhematol.2015.01.003
Kapoor A, Patel DD, Kumar S, Ayyagari A, Dhole TN (2004) Molecular characterization of echovirus 11 isolates from India. Indian J Med Res 119(4):149–156. https://doi.org/10.1007/978-1-62703-269-8
Khodabakhshi AH, Morin RD, Fejes AP, Mungall AJ, Mungall KL, Bolger-Munro M et al (2012) Recurrent targets of aberrant somatic hypermutation in lymphoma. Oncotarget. 3(11):1308–19. https://doi.org/10.18632/oncotarget.653
Kircher M, Witten DM, Jain P, O’roak BJ, Cooper GM, Shendure JJNG (2014) A general framework for estimating the relative pathogenicity of human genetic variants. Nat Genet 46(3):310–5. https://doi.org/10.1038/ng.2892
Kumar P, Henikoff S, Ng PCJNP (2009) Predicting the effects of coding non-synonymous variants on protein function using the SIFT algorithm. Nat Protoc 4(7):1073–81. https://doi.org/10.1038/nprot.2009
Küppers RJNRC (2005) Mechanisms of B-cell lymphoma pathogenesis. Nat Rev Cancer 5(4):251–62. https://doi.org/10.1038/nrc1589
Küppers R, Klein U, Hansmann ML, Rajewsky K (1999) Cellular origin of human B-cell lymphomas. N Engl J Med 341(20):1520–1529. https://doi.org/10.1056/NEJM199911113412007
Ladanyi M, Offit K, Jhanwar SC, Filippa DA, Chaganti RS (1991) MYC rearrangement and translocations involving band 8q24 in diffuse large cell lymphomas
Lenz G, Davis RE, Ngo VN, Lam L, George TC, Wright GW et al (2008) Oncogenic CARD11 mutations in human diffuse large B cell lymphoma. Science 319(5870):1676–1679. https://doi.org/10.1126/science.1153629
Li S, Young KH, Medeiros LJ (2018) Diffuse large B-cell lymphoma. Pathology 50(1):74–8706. https://doi.org/10.1016/j.pathol.2017.09.006
Liu YJ, de Bouteiller O (1997) Fugier-Vivier I 1997 Mechanisms of selection and differentiation in germinal centers. Curr Opin Immunol. 9(2):256–62. https://doi.org/10.1016/s0952-7915(97)80145-8
Liu J, Burrows PD, Wang JY. B cells in immunity and tolerance Wang Y, editor. Vol. 1254(J). Singapore: Springer; 2020
Llinàs-Arias P, Esteller M (2017) Epigenetic inactivation of tumour suppressor coding and non-coding genes in human cancer: an update. Open Biol 7(9):170152. https://doi.org/10.1098/rsob.170152
Maclennan, I. C J R O I (1994) Germinal centers 12:117-39
Miao Y, Medeiros LJ, Li Y, Li J, Young KH (2019) Genetic alterations and their clinical implications in DLBCL. Nat Rev Clin Nncol 16(10):634–52. https://doi.org/10.1038/s41571-019-0225-1
Morin RD, Assouline S, Alcaide M, Mohajeri A, Johnston RL, Chong L et al (2016) Genetic landscapes of relapsed and refractory diffuse large B-cell lymphomas. Clin Cancer Res 22(9):2290–2300. https://doi.org/10.1158/1078-0432.CCR-15-2123
Nakamura T, Tateishi K, Niwa T, Matsushita Y, Tamura K, Kinoshita M et al (2016) Recurrent mutations of CD79B and MYD88 are the hallmark of primary central nervous system lymphomas. Neuropathol Appl Neurobiol 42(3):279–290. https://doi.org/10.1111/nan.12259
Ng PC, Henikoff SJGR (2002) Accounting for human polymorphisms predicted to affect protein function. Genome Res 12(3):436–446. https://doi.org/10.1101/gr.212802
Ng PC, Henikoff SJNAR (2003) SIFT: predicting amino acid changes that affect protein function. Nucleic Acids Res. 31(13):3812–4. https://doi.org/10.1093/nar/gkg509
Nogai H, Dörken B, Lenz G (2011) Pathogenesis of non-Hodgkin’s lymphoma. J Clin Oncol 29(14):1803–1811. https://doi.org/10.1200/JCO.2010.33.3252
Ott G, Rosenwald A, Campo E (2013) Understanding MYC-driven aggressive B-cell lymphomas: pathogenesis and classification. Blood J Am Soc Hematol 122(24):3884–91
Pasqualucci LJIR (2019) Molecular pathogenesis of germinal center-derived B cell lymphomas. Immunol Rev 288(1):240–61. https://doi.org/10.1111/imr.12745
Pasqualucci L (2019) Molecular pathogenesis of germinal center-derived B cell lymphomas. Immunol Rev 288(1):240–61
Pasqualucci L, Dalla-Favera R (2015) The genetic landscape of diffuse large B-cell lymphoma. Semin Hematol 52(2):67–76. https://doi.org/10.1053/j.seminhematol.2015.01.005
Pasqualucci L, Dalla-Favera RJB (2018) Genetics of diffuse large B-cell lymphoma. Blood 131(21):2307–19. https://doi.org/10.1182/blood-2017-11-764332
Pasqualucci L, Dominguez-Sola D, Chiarenza A, Fabbri G, Grunn A, Trifonov V et al (2011) Inactivating mutations of acetyltransferase genes in B-cell lymphoma. Nature 471(7337):189–95. https://doi.org/10.1038/nature09730
Pelengaris S, Khan M, Evan GJNRC (2002) c-MYC: more than just a matter of life and death. Nat Rev Cancer 2(10):764–76. https://doi.org/10.1038/nrc904
Pieper K, Grimbacher B, Eibel H (2013) B-cell biology and development. J Allergy Clin Immunol 131(4):959–71
Radaev S, Zou Z, Tolar P, Nguyen K, Nguyen A, Krueger PD et al (2010) Structural and functional studies of Igalphabeta and its assembly with the B cell antigen receptor. Structure 18(8):934–943. https://doi.org/10.1016/j.str.2010.04.019
Roche MI, Ramadas RA, Medoff BD. The role of CARMA1 in T cells. Crit Rev™ Immunol 2013;33(3).
Reddy A, Zhang J, Davis NS, Moffitt AB, Love CL, Waldrop A, Dave SS (2017) Genetic and functional drivers of diffuse large B cell lymphoma. Cell 171(2):481–494. https://doi.org/10.1016/j.cell.2017.09.027
Ritchie GR, Dunham I, Zeggini E, Flicek PJNM (2014) Functional annotation of noncoding sequence variants. Nat Methods 11(3):294–296. https://doi.org/10.1038/nmeth.2832
Rosenwald A, Wright G, Leroy K, Yu X, Gaulard P, Gascoyne RD et al (2003) Molecular diagnosis of primary mediastinal B cell lymphoma identifies a clinically favorable subgroup of diffuse large B cell lymphoma related to Hodgkin lymphoma. J Exp Med 198(6):851–862. https://doi.org/10.1084/jem.20031074
Safaei S, Baradaran B, Hagh MF, Alivand MR, Talebi M, Gharibi T, Solali S (2018) Double sword role of EZH2 in leukemia. Biomedicine & Pharmacotherapy. 98:626–35
Salvaris R, Ong J, Gregory GP (2021) Bispecific antibodies: a review of development, clinical efficacy and toxicity in B-cell lymphomas. J Pers Med 11(5):355. https://doi.org/10.3390/jpm11050355
Schuetz JM, Johnson NA, Morin RD, Scott DW, Tan K, Ben-Nierah S et al (2012) BCL2 mutations in diffuse large B-cell lymphoma. Leukemia 26(6):1383–1390. https://doi.org/10.1038/leu.2011.378
Schweighoffer E, Tybulewicz VL (2018) Signalling for B cell survival. Curr OpinCell Biol 51:8–14. https://doi.org/10.1016/j.ceb.2017.10.002
Seifert M, Scholtysik R, Küppers R. Chapter 1 Origin and pathogenesis of B cell lymphomas 2014. https://doi.org/10.1007/978-1-62703-269-8
Sesques P, Johnson NA (2017) Approach to the diagnosis and treatment of high-grade B-cell lymphomas with MYC and BCL2 and/or BCL6 rearrangements, The Journal of the American Society of Hematology. Blood 129(3):280–288. https://doi.org/10.1182/blood-2016-02-636316
Shaffer AL III, Young RM, Staudt LM (2012) Pathogenesis of human B cell lymphomas. Annu Rev Immunol 30:565–610. https://doi.org/10.1146/annurev-immunol-020711-075027
Shapiro-shelef M, Calame K (2005) Regulation of plasma-cell development. Nat Rev Immunol 5(3):230–242. https://doi.org/10.1038/nri1572
Sim NL, Kumar P, Hu J, Henikoff S, Schneider G, Ng PC (2012) SIFT web server: predicting effects of amino acid substitutions on proteins. Nucleic Acids Res 40(W1):W452-7. https://doi.org/10.1093/nar/gks539
Singh R, Letai A, Sarosiek K (2019) Regulation of apoptosis in health and disease: the balancing act of BCL-2 family proteins. Nat Rev Mol Cell Biol 20(3):175–93. https://doi.org/10.1038/s41580-018-0089-8
Sterner DE, Wang X, Bloom MH, Simon GM, Berger SL (2002) The SANT domain of Ada2 is required for normal acetylation of histones by the yeast SAGA complex. J Biol Chem 277(10):8178–86. https://doi.org/10.1074/jbc.M108601200
Sun R, Medeiros LJ, Young KH (2016) Diagnostic and predictive biomarkers for lymphoma diagnosis and treatment in the era of precision medicine. Mod Pathol 29(10):1118–1142. https://doi.org/10.1038/modpathol.2016.92
Swerdlow SH, Campo E, Pileri SA, Harris NL, Stein H, Siebert R et al (2016) The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood 127(20):2375–2390. https://doi.org/10.1182/blood-2016-01-643569
Tansey WP (2014) Mammalian MYC proteins and cancer. New J Sci 2014:27. https://doi.org/10.1155/2014/757534
Tate JG, Bamford S, Jubb HC, Sondka Z, Beare DM, Bindal N et al (2019) COSMIC: the catalogue of somatic mutations in cancer. Nucleic Acids Res 47(D1):D941–D947. https://doi.org/10.1093/nar/gky1015
Thakur A, Huang M, Lum LG (2018) Bispecific antibody-based therapeutics: strengths and challenges. Blood Rev 32(4):339–347. https://doi.org/10.1016/j.blre.2018.02.004
Vale AM, Kearney JF, Nobrega A, Schroeder HW (2015) Development and function of B cell subsets. Elsevier, Molecular biology of B cells
Vari F, Arpon D, Keane C, Hertzberg MS, Talaulikar D, Jain S et al (2018) Immune evasion via PD-1/PD-L1 on NK cells and monocyte/macrophages is more prominent in Hodgkin lymphoma than DLBCL. Blood the J Am Soc Hematol 131(16):1809–1819
Vermaat JS, Somers SF, de Wreede LC, Kraan W, de Groen RAL, Schrader AMR et al (2020) MYD88 mutations identify a molecular subgroup of diffuse large B-cell lymphoma with an unfavorable prognosis. Haematologica 105(2):424–434. https://doi.org/10.3324/haematol.2018.214122
Wang H, Kaur G, Sankin AI, Chen F, Guan F, Zang X (2019) Immune checkpoint blockade and CAR-T cell therapy in hematologic malignancies. J Hematol Oncol 12(1):59. https://doi.org/10.1186/s13045-019-0746-1
Wang J-Y (2020) B cells in immunity and tolerance. Springer; 2020
Weyhenmeyer B, Murphy AC, Prehn JH, Murphy BM (2012) Targeting the anti-apoptotic Bcl-2 family members for the treatment of cancer. Exp Oncol 34(3):192–9
Wu D, Qiu Y, Jiao Y, Qiu Z, Liu D (2020) Small molecules targeting HATs, HDACs, and BRDs in cancer therapy. Front Oncol 11(10):560487. https://doi.org/10.3389/fonc.2020.560487
Xu W, Berning P, Lenz G (2021) Targeting B-cell receptor and PI3K signaling in diffuse large B-cell lymphoma. Blood 138(13):1110–1119. https://doi.org/10.1182/blood.2020006784
Yam-puc JC, Zhang L, Zhang Y, Toellner KM (2018) Role of B-cell receptors for B-cell development and antigen-induced differentiation. F1000Res 7:429. https://doi.org/10.12688/f1000research.13567.1
Yu LM, Chang TW (1992) Human mb-1 gene: complete cDNA sequence and its expression in B cells bearing membrane Ig of various isotypes. J Immunol 148(2):633–637. https://doi.org/10.4049/jimmunol.148.2.633
Author information
Authors and Affiliations
Corresponding author
Additional information
Communicated by Ewa Ziętkiewicz
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Supplementary Information
Below is the link to the electronic supplementary material.
Rights and permissions
Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
About this article
Cite this article
Almasmoum, H.A. Molecular complexity of diffuse large B-cell lymphoma: a molecular perspective and therapeutic implications. J Appl Genetics 65, 57–72 (2024). https://doi.org/10.1007/s13353-023-00804-5
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s13353-023-00804-5